GID Group’s SVF-2 device and therapy, pending FDA approval, gives providers and patients a major development in cellular medicine to help treat osteoarthritis pain and to delay or provide an alternative to total knee replacement surgery. GID’s technology harvests, isolate and reimplants the right type and combination of one’s own healing cells. Our first FDA-approved pivotal clinical study, a closely watched rigorous trial, had no serious adverse events and showed significant improvements in pain and function. The FDA has granted conditional approval for a second final pivotal clinical trial. Cellular therapy addresses an unmet need in 14 million people living with osteoarthritis of the knee, offering a less time consuming, painful and costly treatment for everyone that requires no joint surgery and no drugs for osteoarthritis pain. Help relieve the $200 billion burden of osteoarthritis management on our healthcare system. Heal intelligently.